147 related articles for article (PubMed ID: 32852209)
1. Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression.
Kilic O; Matos de Souza MR; Almotlak AA; Wang Y; Siegfried JM; Distefano MD; Wagner CR
J Med Chem; 2020 Sep; 63(18):10235-10245. PubMed ID: 32852209
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
3. Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.
Petersburg JR; Shen J; Csizmar CM; Murphy KA; Spanier J; Gabrielse K; Griffith TS; Fife B; Wagner CR
ACS Nano; 2018 Jul; 12(7):6563-6576. PubMed ID: 29792808
[TBL] [Abstract][Full Text] [Related]
4. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
5. Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
Mølgaard K; Harwood SL; Compte M; Merino N; Bonet J; Alvarez-Cienfuegos A; Mikkelsen K; Nuñez-Prado N; Alvarez-Mendez A; Sanz L; Blanco FJ; Alvarez-Vallina L
Cancer Immunol Immunother; 2018 Aug; 67(8):1251-1260. PubMed ID: 29869168
[TBL] [Abstract][Full Text] [Related]
6. Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.
Mews EA; Beckmann P; Patchava M; Wang Y; Largaespada DA; Wagner CR
ACS Nano; 2022 Aug; 16(8):12185-12201. PubMed ID: 35876221
[TBL] [Abstract][Full Text] [Related]
7. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in
Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416
[TBL] [Abstract][Full Text] [Related]
8. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
[TBL] [Abstract][Full Text] [Related]
10. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Rubio-Pérez L; Lázaro-Gorines R; Harwood SL; Compte M; Navarro R; Tapia-Galisteo A; Bonet J; Blanco B; Lykkemark S; Ramírez-Fernández Á; Ferreras-Gutiérrez M; Domínguez-Alonso C; Díez-Alonso L; Segura-Tudela A; Hangiu O; Erce-Llamazares A; Blanco FJ; Santos C; Rodríguez-Peralto JL; Sanz L; Álvarez-Vallina L
Oncoimmunology; 2023; 12(1):2205336. PubMed ID: 37114242
[TBL] [Abstract][Full Text] [Related]
11. Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.
Li Q; So CR; Fegan A; Cody V; Sarikaya M; Vallera DA; Wagner CR
J Am Chem Soc; 2010 Dec; 132(48):17247-57. PubMed ID: 21077608
[TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
13. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
14. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
16. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
17. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2021; 12():669496. PubMed ID: 34040611
[TBL] [Abstract][Full Text] [Related]
18. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
19. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
20. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
